Related Experiment Video

Updated: Aug 26, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy

Harald Wajant1

  • 1Department of Molecular Medicine Medical Polyclinic, University of Wuerzburg Roentgenring 11, 97070 Wuerzburg, Germany. harald.wajant@mail.uni-wuerzburg.de

Molecular Interventions
|March 3, 2004
PubMed

Insights

Ovarian tumors can resist cell death signals from tumor necrosis factor-alpha (TNF-alpha) by overexpressing FLIP. This protein blocks apoptosis, promoting tumor progression and potentially hindering cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Tumor necrosis factor-alpha (TNF-alpha) can trigger apoptosis in ovarian cancer cells.
  • However, many ovarian malignancies exhibit resistance to TNF-alpha-induced cell death.
  • Understanding resistance mechanisms is crucial for effective ovarian cancer therapy.

Purpose of the Study:

  • To elucidate the mechanisms by which ovarian tumors evade death receptor-mediated apoptosis.
  • To investigate the role of FLIP in conferring resistance to TNF-alpha signaling.
  • To identify potential therapeutic targets for overcoming apoptosis resistance in ovarian cancer.

Main Methods:

  • Analysis of signaling pathways involved in death receptor-mediated apoptosis.
  • Assessment of FLIP protein levels in ovarian cancer cells.
  • Investigation of the interaction between FLIP, FLICE, and caspase activation.

Main Results:

  • Ovarian tumors resist TNF-alpha-induced apoptosis by blocking extracellular signal transduction before caspase activation.
  • Overexpression of FLIP (FLICE-inhibitory protein) is identified as a key mediator of this resistance.
  • FLIP effectively inhibits the activity of caspase-8 (FLICE), preventing the apoptotic cascade.

Conclusions:

  • FLIP acts as a tumor progression factor by preventing programmed cell death in ovarian malignancies.
  • Targeting FLIP-mediated apoptosis blockade could represent a novel therapeutic strategy for ovarian cancer.
  • Overcoming FLIP-induced resistance may improve treatment outcomes and patient prognoses.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...